• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Endologix shares gain 5 points in days following Q2 report

Endologix shares gain 5 points in days following Q2 report

August 6, 2013 By Sony Salzman

Endologix logo

Endologix (NSDQ:ELGX) beat Wall Street estimates by 2 cents and cut losses in the 2nd quarter, sending share prices up 5.3% to almost $16 in the days following the earnings results.

Analysis pegged the Irvine, Calif.-based company’s adjusted per-share losses at -5¢ for Q2, but Endologix beat that estimate by 2¢. The device maker leveled with investors by changing the estimated "fair value" of a new acquisition, accepting a $7.6 million hit to the books for the goodwill adjustment.

The company’s GAAP numbers tell an even cheerier story, showing not only a trimming of losses but a swing to black. For the 2nd quarter 2013 Endologix posted profits of $5.7 million, or 9¢ per diluted share, on sales of $34 million. That’s a 33% increase in sales and a swing to black in compared with the same period last year, when Endologix posted losses of $6.7 million, or -11¢ per share, on sales of $25.5 million.

Endologix, which specialized in grafts to treat aneurysms, partially attributed the discrepancy between GAAP and non-GAAP results to a "decrease in fair value of the contingent consideration (solely payable in the form of our common stock) related to the Nellix acquisition," according to SEC filings.

"Our 2nd quarter revenue was in-line with preliminary results released earlier this month," said CEO John McDermott in the regulatory filing. "In Europe, our controlled market release of the Nellix EndoVascular Aneurysm Sealing System is tracking to plan, providing us an excellent opportunity to further enhance the procedure and training ahead of a broader commercial launch anticipated in 2014."

ELGX shares closed at a 0.7% increase on the day yesterday, trading at $16.03 apiece. That’s a 5.3% bump since the morning prior to the company’s earnings release, when shares opened at $15.23.

Filed Under: MassDevice Earnings Roundup, News Well, Wall Street Beat Tagged With: 2013, Endologix, Q2

More recent news

  • Real-world data backs Route 92 reperfusion system
  • LivsMed unveils new surgical robot with telesurgery capabilities
  • JenaValve enrolls first patient in TAVR for AR study
  • HistoSonics expands insurance coverage for histotripsy treatment
  • Johnson & Johnson MedTech gets updated FDA nod for Varipulse PFA

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy